Antisecretory Factor for Treatment of Peritumoral Edema in Glioblastoma Patients

Overview

Journal Acta Neurochir (Wien)

Specialty Neurosurgery

Date 2025 Mar 8

PMID 40056235

Authors

Louise Carstam

Tomas Gomez Vecchio

Monika Lyczak

Hanna Aberg

Asgeir S Jakola

Eva Jennische

Stefan Lange

Kliment Gatzinsky

Affiliations

Soon will be listed here.

Abstract

Purpose: Glioblastoma (GBM) is an aggressive brain tumor often accompanied by a vasogenic peritumoral edema, which contributes to symptoms both at diagnosis and during later stages of the disease. Previous studies have suggested effectiveness of the endogenous protein, Antisecretory Factor (AF), in reducing the intracranial pressure in cytotoxic brain edema after trauma. Interestingly, AF also seems to carry antineoplastic effects in experimental GBM models. This study investigated whether AF reduces peritumoral edema in GBM patients. As a secondary aim, we assessed potential effects on tumor progression by AF.

Methods: Fifteen newly diagnosed GBM patients were treated for 7 days preoperatively with AF in addition to standard of care (SOC) treatment with corticosteroids. The change in edema volume was assessed volumetrically using T2/FLAIR weighted MRI and compared to a control group of 10 GBM patients receiving SOC only.

Results: At baseline the mean tumor volume for the entire cohort was 35.7 cm3 with a mean edema of 62.2 cm3. There was no significant difference in edema volume change between the AF treated patients, who demonstrated a mean edema reduction of 7.1cm3 (95%CI -5.4-19.6), and the controls, 11.3cm3 (95%CI -0.8-23.5), p = 0.61. No difference was observed in tumor volume change between the two groups, p = 0.79. No adverse treatment effects were noted.

Conclusion: Treatment with AF in addition to SOC does not seem to reduce the peritumoral edema in GBM patients. The treatment was well tolerated. The lack of edema-reducing effect may be related to the different pathophysiological properties of vasogenic and cytotoxic edema.

References

Hui C, Rudra S, Ma S, Campian J, Huang J . Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients. J Neurooncol. 2019; 143(1):129-136. DOI: 10.1007/s11060-019-03146-7. View

Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J, Pujol S . 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012; 30(9):1323-41. PMC: 3466397. DOI: 10.1016/j.mri.2012.05.001. View

Eriksson A, Shafazand M, Jennische E, Lonnroth I, Lange S . Antisecretory factor-induced regression of Crohn's disease in a weak responder to conventional pharmacological treatment. Inflamm Bowel Dis. 2003; 9(6):398-400. DOI: 10.1097/00054725-200311000-00013. View

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster C . Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4):457-65. DOI: 10.1517/14740338.2016.1140743. View

Eriksson A, Shafazand M, Jennische E, Lange S . Effect of antisecretory factor in ulcerative colitis on histological and laborative outcome: a short period clinical trial. Scand J Gastroenterol. 2003; 38(10):1045-9. DOI: 10.1080/00365520310005064. View

Omuro A, DeAngelis L . Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842-50. DOI: 10.1001/jama.2013.280319. View

Clausen F, Hansson H, Raud J, Marklund N . Intranasal Administration of the Antisecretory Peptide AF-16 Reduces Edema and Improves Cognitive Function Following Diffuse Traumatic Brain Injury in the Rat. Front Neurol. 2017; 8:39. PMC: 5306199. DOI: 10.3389/fneur.2017.00039. View

Low J, Ostrom Q, Cioffi G, Neff C, Waite K, Kruchko C . Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022; 9(3):165-182. PMC: 9113389. DOI: 10.1093/nop/npac015. View

Johansson E, Al-Olama M, Hansson H, Lange S, Jennische E . Diet-induced antisecretory factor prevents intracranial hypertension in a dosage-dependent manner. Br J Nutr. 2012; 109(12):2247-52. DOI: 10.1017/S0007114512004552. View

10.

Eide P, Eidsvaag V, Hansson H . Antisecretory factor (AF) exerts no effects on intracranial pressure (ICP) waves and ICP in patients with idiopathic normal pressure hydrocephalus and idiopathic intracranial hypertension. J Neurol Sci. 2014; 343(1-2):132-7. DOI: 10.1016/j.jns.2014.05.054. View

11.

Ilkhanizadeh S, Sabelstrom H, Miroshnikova Y, Frantz A, Zhu W, Idilli A . Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. Mol Cancer Res. 2018; 16(5):777-790. PMC: 5932284. DOI: 10.1158/1541-7786.MCR-17-0413. View

12.

Rungta R, Choi H, Tyson J, Malik A, Dissing-Olesen L, Lin P . The cellular mechanisms of neuronal swelling underlying cytotoxic edema. Cell. 2015; 161(3):610-621. DOI: 10.1016/j.cell.2015.03.029. View

13.

Zaman S, Aamir K, Hanson L, Lange S . High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment. Int J Infect Dis. 2018; 71:48-52. DOI: 10.1016/j.ijid.2018.03.015. View

14.

Pitter K, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell S, Donnola S . Corticosteroids compromise survival in glioblastoma. Brain. 2016; 139(Pt 5):1458-71. PMC: 5006251. DOI: 10.1093/brain/aww046. View

15.

Kim M, Wasling P, Xiao M, Jennische E, Lange S, Hanse E . Antisecretory factor modulates GABAergic transmission in the rat hippocampus. Regul Pept. 2005; 129(1-3):109-18. DOI: 10.1016/j.regpep.2005.01.018. View

16.

Arvold N, Armstrong T, Warren K, Chang S, DeAngelis L, Blakeley J . Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018; 20(7):897-906. PMC: 6007454. DOI: 10.1093/neuonc/noy056. View

17.

Ehinger E, Kopecky J, Darabi A, Visse E, Edvardsson C, Tomasevic G . Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma. BMC Neurol. 2023; 23(1):76. PMC: 9938624. DOI: 10.1186/s12883-023-03119-4. View

18.

Rabinstein A . Treatment of cerebral edema. Neurologist. 2006; 12(2):59-73. DOI: 10.1097/01.nrl.0000186810.62736.f0. View

19.

Lonnroth I, Lange S . Purification and characterization of the antisecretory factor: a protein in the central nervous system and in the gut which inhibits intestinal hypersecretion induced by cholera toxin. Biochim Biophys Acta. 1986; 883(1):138-44. DOI: 10.1016/0304-4165(86)90144-3. View

20.

Michinaga S, Koyama Y . Pathogenesis of brain edema and investigation into anti-edema drugs. Int J Mol Sci. 2015; 16(5):9949-75. PMC: 4463627. DOI: 10.3390/ijms16059949. View